Reversible posterior encephalopathy syndrome associated with bortezomib.
Reversible posterior encephalopathy (RPES) is an uncommon neurological syndrome that is being increasingly reported in association with anti-neoplastic therapies. The first case of reversible posterior encephalopathy associated with the proteosome inhibitor bortezomib is described and the reported experience of the occurrence of RPES with other antineoplastic therapies reviewed. Dysregulation of cerebral vasomotor autoregulation is postulated as the underlying pathophysiology in this case of bortezomib associated RPES.
Terwiel
E
E
Department of Haematology, The Canberra Hospital, Woden, Australian Capital Territory, Australia.
Hanrahan
R
R
Lueck
C
C
D'Rozario
J
J
D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D005260:Female; D006801:Humans; D020343:Hypertensive Encephalopathy / Q000139:chemically induced* / Q000175:diagnosis*; D008875:Middle Aged; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced* / Q000175:diagnosis*; D011719:Pyrazines / Q000009:adverse effects*
D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib